Literature DB >> 20538373

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

A Caroli1, G B Frisoni.   

Abstract

The aim of this study was to investigate the dynamics of four of the most validated biomarkers for Alzheimer's disease (AD), cerebro-spinal fluid (CSF) Abeta 1-42, tau, hippocampal volume, and FDG-PET, in patients at different stage of AD. Two hundred twenty-nine cognitively healthy subjects, 154 mild cognitive impairment (MCI) patients converted to AD, and 193 (95 early and 98 late) AD patients were selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For each biomarker, individual values were Z-transformed and plotted against ADAS-cog scores, and sigmoid and linear fits were compared. For most biomarkers the sigmoid model fitted data significantly better than the linear model. Abeta 1-42 time course followed a steep curve, stabilizing early in the disease course. CSF tau and hippocampal volume changed later showing similar monotonous trends, reflecting disease progression. Hippocampal loss trend was steeper and occurred earlier in time in APOE epsilon4 carriers than in non-carriers. FDG-PET started changing early in time and likely followed a linear decline. In conclusion, this study provides the first evidence in favor of the dynamic biomarker model which has recently been proposed. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538373      PMCID: PMC3467365          DOI: 10.1016/j.neurobiolaging.2010.04.024

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  52 in total

1.  Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study.

Authors:  K M Gosche; J A Mortimer; C D Smith; W R Markesbery; D A Snowdon
Journal:  Neurology       Date:  2002-05-28       Impact factor: 9.910

2.  Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

Authors:  H Arai; M Terajima; M Miura; S Higuchi; T Muramatsu; N Machida; H Seiki; S Takase; C M Clark; V M Lee
Journal:  Ann Neurol       Date:  1995-10       Impact factor: 10.422

3.  Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia.

Authors:  Yuan-Yu Hsu; Norbert Schuff; An-Tao Du; Kevin Mark; Xiaoping Zhu; Dawn Hardin; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2002-09       Impact factor: 4.813

4.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Authors:  Christopher M Clark; Sharon Xie; Jesse Chittams; Douglas Ewbank; Elaine Peskind; Douglas Galasko; John C Morris; Daniel W McKeel; Martin Farlow; Sharon L Weitlauf; Joseph Quinn; Jeffrey Kaye; David Knopman; Hiroyuki Arai; Rachelle S Doody; Charles DeCarli; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2003-12

5.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

6.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Authors:  E M Reiman; R J Caselli; L S Yun; K Chen; D Bandy; S Minoshima; S N Thibodeau; D Osborne
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

7.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.

Authors:  G W Small; J C Mazziotta; M T Collins; L R Baxter; M E Phelps; M A Mandelkern; A Kaplan; A La Rue; C F Adamson; L Chang
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

8.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

9.  Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.

Authors:  M Ingelsson; H Fukumoto; K L Newell; J H Growdon; E T Hedley-Whyte; M P Frosch; M S Albert; B T Hyman; M C Irizarry
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

10.  Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study.

Authors:  Dennis Chan; John C Janssen; Jennifer L Whitwell; Hilary C Watt; Rhian Jenkins; Chris Frost; Martin N Rossor; Nick C Fox
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

View more
  56 in total

1.  Shapes of the trajectories of 5 major biomarkers of Alzheimer disease.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman
Journal:  Arch Neurol       Date:  2012-07

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

3.  Measuring longitudinal change in the hippocampal formation from in vivo high-resolution T2-weighted MRI.

Authors:  Sandhitsu R Das; Brian B Avants; John Pluta; Hongzhi Wang; Jung W Suh; Michael W Weiner; Susanne G Mueller; Paul A Yushkevich
Journal:  Neuroimage       Date:  2012-01-28       Impact factor: 6.556

4.  Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.

Authors:  Ying Liu; Lan Tan; Hui-Fu Wang; Yong Liu; Xiao-Ke Hao; Chen-Chen Tan; Teng Jiang; Bing Liu; Dao-Qiang Zhang; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

5.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

6.  CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.

Authors:  Nikki H Stricker; Hiroko H Dodge; N Maritza Dowling; S Duke Han; Elena A Erosheva; William J Jagust
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

7.  Longitudinal change of biomarkers in cognitive decline.

Authors:  Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Arch Neurol       Date:  2011-06-13

8.  Evidence for ordering of Alzheimer disease biomarkers.

Authors:  Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Paul S Aisen; John Q Trojanowski; Leslie M Shaw; Matthew A Bernstein; Ronald C Petersen; Michael W Weiner; David S Knopman
Journal:  Arch Neurol       Date:  2011-08-08

9.  The dynamics of cortical and hippocampal atrophy in Alzheimer disease.

Authors:  Mert R Sabuncu; Rahul S Desikan; Jorge Sepulcre; Boon Thye T Yeo; Hesheng Liu; Nicholas J Schmansky; Martin Reuter; Michael W Weiner; Randy L Buckner; Reisa A Sperling; Bruce Fischl
Journal:  Arch Neurol       Date:  2011-08

10.  Regional covariance patterns of gray matter alterations in Alzheimer's disease and its replicability evaluation.

Authors:  Xiaojuan Guo; Kewei Chen; Yumei Zhang; Yan Wang; Li Yao
Journal:  J Magn Reson Imaging       Date:  2013-04-15       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.